Phone (336) 292-1510
Fax (336) 292-0679

Receive our eNewsletter

  Home  
  Our Team  
  Patient Info  
  Services  

News for Healthier Living

Mount Sinai Study Reveals Why Some Myeloma Patients Stay Cancer-Free for Years After CAR T Therapy

A new study from the Icahn School of Medicine at Mount Sinai helps explain why some people with multiple myeloma, a type of blood cancer, stay in remission for many years after receiving CAR T cell therapy, while others see their cancer return sooner. Published in Blood Advances, the research is the first longitudinal, single-cell, multi-omic study of cilta-cel in multiple myeloma. Cilta-cel (ciltacabtagene autoleucel) is a type of CAR T cell therapy used to treat relapsed or refractory multiple myeloma. It works by using a patient's own T cells, which are genetically engineered in a lab to target and kill cancer cells that have B cell maturation antigen (BCMA) on their surface. The modified T cells are then infused back into the patient as a one-time treatment to fight the cancer.

November 12, 2025


November 16 2025

November 15 2025

November 14 2025

November 13 2025

November 12 2025

November 11 2025

November 10 2025

November 9 2025

November 8 2025

November 7 2025

November 6 2025

November 5 2025

November 4 2025

November 3 2025

November 2 2025